Search Follow us

Key contacts

Klaus Schinkel

Klaus Schinkel
Director, Head of Germany

Regional office - Europe
Schumannstrasse 34b
60325, Frankfurt
Germany
Tel: +49 (0)69 78 8076 960
kschinkel@edisongroup.com

European listed companies

Biotie Therapies Corp Vivalis
NorDiag Thales
Orexo AB Science
Genfit Diaxonhit
Hutchison China MediTech EADS
Global Bioenergies Stallergenes
Core Laboratories Plaza Centers
Outotec Stentys
Albioma Erytech Pharma
Prodware Store Electronic Systems
See more

Companies with HQs in europe

Stobart Group GB Group
Travel & Leisure Financials
Technology Pharmaceutical & healthcare
Vertu Motors Ixico
Lookers IQE
Cohort Ebiquity
Trifast Vernalis
Share Park Group
Walker Greenbank Mondo TV
Aberdeen New Thai Investment Trust Touchstone Innovations
See more

Latest research

EMIS Group

Solid H1; on track to meet FY18 expectations

Update | Technology | 17/07/2018

In H118, EMIS traded in line with management’s expectations and generated year-on-year revenue growth. All divisions saw solid performance and management expects to meet FY18 expectations. The company continues to work on developing longer-term growth plans; these will be key to reinvigorating revenue and earnings growth, which in our view will be the trigger to closing the valuation discount versus peers.

Allium Medical Solutions

Continuing to execute on an ambitious plan

Outlook | Pharmaceutical & healthcare | 17/07/2018

Following broad FDA approval for Gardia, Allium anticipates the publication of clinical study results in a leading cardiology journal. Allium believes this will further increase Gardia’s attractiveness for both physicians and potential partners. Allium has secured approval for most of its urology stents and soft tissue fixation products in its main markets. We expect additional product approvals during 2018 and sales growth from its distribution deals in new and established markets. Allium’s…

Transgene

Near-term data to define long-term strategy

Outlook | Pharmaceutical & healthcare | 16/07/2018

Transgene develops virus-based product candidates for use in oncology and infectious diseases, its five clinical products are currently in 11 clinical trials across a variety of indications, its most advanced is Phase III trial with Pexa-Vec in first-line Hepatocellular Carcinoma with data anticipated in 2019. Its strategy remains to develop its candidates in combination with approved treatments, notably immune checkpoint inhibitors (ICIs). It anticipates eight clinical readouts across its five clinical…

RCM Beteiligungs

Playing smart

Update | Financials | 16/07/2018

Ahead of H1 results on 15 August, Q1 showed the success of RCM Beteiligungs’ strategic focus on certain well-defined projects. Quarterly PBT of €2.3m, which alone exceeded full-year 2017 thanks to a c €11m development sale, all but guarantees guidance of more than €3m PBT in 2018. Driven by favourable macro factors and scope for efficiencies, asset development and appreciation, RCM’s positive outlook is reflected in confirmation of a 50% dividend hike for last year.…

JPMorgan European Smaller Companies Trust

Building on long-term positive track record

Review | Investment Companies | 16/07/2018

JPMorgan European Smaller Companies Trust (JESC) aims to generate long-term capital growth from a portfolio of high-quality, reasonably valued, small-cap European equities. While the European stock market, in keeping with global markets, has been more volatile year to date compared with the abnormally low levels of volatility in 2017, the managers believe that there is potential for further upside. They cite an improving European and global economy, low inflation and a benign interest rate environment,…

About

Edison first opened its German office in Berlin in 2011. Now based in Frankfurt, we continue to provide research services to companies listed on mainland European stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports